Evidence map›Paper›PMID 32386119›Full record

Trial reportPediatric blood & cancer2020

Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update.

Danielle Novetsky Friedman, Meier Hsu, Chaya S Moskowitz, Jasmine H Francis, Eric Lis, Megan Harlan Fleischut, Kevin C Oeffinger, Michael Walsh, Emily S Tonorezos, Charles A Sklar and 2 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Pediatric blood & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. [Whole-body MRI in cancer predisposition syndromes].Radiologie (Heidelberg, Germany) · 2022
    Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Danielle Novetsky FriedmanMemorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4668-9176
Meier HsuMemorial Sloan Kettering Cancer Center, New York, New York.
Chaya S MoskowitzMemorial Sloan Kettering Cancer Center, New York, New York.
Jasmine H FrancisMemorial Sloan Kettering Cancer Center, New York, New York.
Eric LisMemorial Sloan Kettering Cancer Center, New York, New York.
Megan Harlan FleischutMemorial Sloan Kettering Cancer Center, New York, New York.
Kevin C OeffingerDuke Cancer Institute, Duke, North Carolina.
Michael WalshMemorial Sloan Kettering Cancer Center, New York, New York.
Emily S TonorezosMemorial Sloan Kettering Cancer Center, New York, New York.
Charles A SklarMemorial Sloan Kettering Cancer Center, New York, New York.
David H AbramsonMemorial Sloan Kettering Cancer Center, New York, New York.
Ira J DunkelMemorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · USDuke Energy (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundGermline retinoblastoma (Rb) survivors are at lifelong risk for developing subsequent malignancies (SMNs). Optimal surveillance modalities are needed to detect SMN at an early stage in this high-risk cohort. We investigated the use of rapid whole-body magnetic resonance imaging (WB-MRI) as a noninvasive screening modality in this cohort. PROCEDURE: WB-MRI was performed in asymptomatic preadolescent, adolescent, or young adult survivors of germline Rb from February 1, 2008 to December 31, 2018 at a tertiary cancer center. We calculated sensitivity and specificity of WB-MRI and rate of false-positive findings requiring additional evaluation.

resultsOverall, 110 WB-MRI were performed in 47 germline Rb survivors (51% female; median age at initial WB-MRI: 15.5 years [range 8-25.3]). Patients received 1-10 annual WB-MRI examinations (median: two). Thirteen patients had an abnormal WB-MRI; three findings were deemed to be likely benign and were not evaluated further. Ten patients required dedicated imaging and three required biopsy; two patients were diagnosed with localized high-grade osteosarcoma, while the other eight had benign findings. One patient was diagnosed with secondary osteosarcoma 3 months after normal WB-MRI. In total, there were 96 true negatives, 11 false positives, two true positives, and one false negative. The sensitivity of WB-MRI in this cohort was 66.7% (95% confidence interval [CI], 14.2-96.0) and the specificity was 89.7% (95% CI, 83.6-93.7).

conclusionsBased on our 10-year experience, surveillance WB-MRI appears to have limited utility as a surveillance modality for SMN in germline Rb survivors. Alternate screening modalities should be investigated.

Indexed as

AdolescentAdultCancer SurvivorsChildFemaleFollow-Up StudiesGerm CellsHumansIncidenceMagnetic Resonance ImagingMaleNeoplasms, Second PrimaryNew YorkPopulation SurveillancePrognosisRetinal Neoplasmsretinoblastomasecond cancerssurveillancesurvivorshipwhole-body MRI

Identifiers

PMID32386119
PMCPMC8177753
OpenAlexW3021776769

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.